Short Interest in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Rises By 30.5%

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) was the recipient of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 109,200 shares, an increase of 30.5% from the December 15th total of 83,700 shares. Currently, 0.7% of the company’s shares are sold short. Based on an average trading volume of 625,300 shares, the short-interest ratio is currently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Sensei Biotherapeutics in a report on Wednesday, January 8th.

Institutional Investors Weigh In On Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. National Bank of Canada FI raised its position in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 355.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 45,575 shares of the company’s stock after purchasing an additional 35,575 shares during the quarter. National Bank of Canada FI owned 0.18% of Sensei Biotherapeutics worth $27,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Price Performance

Shares of Sensei Biotherapeutics stock traded up $0.00 on Thursday, hitting $0.51. The company had a trading volume of 87,242 shares, compared to its average volume of 1,253,854. The stock has a 50-day moving average of $0.50 and a 200-day moving average of $0.55. Sensei Biotherapeutics has a twelve month low of $0.38 and a twelve month high of $1.94. The firm has a market capitalization of $12.80 million, a P/E ratio of -0.43 and a beta of 0.17.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.